274 related articles for article (PubMed ID: 30641718)
1. The influence of subclinical hypothyroidism on serum lipid profile, PCSK9 levels and CD36 expression on monocytes.
Fazaeli M; Khoshdel A; Shafiepour M; Rohban M
Diabetes Metab Syndr; 2019; 13(1):312-316. PubMed ID: 30641718
[TBL] [Abstract][Full Text] [Related]
2. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
[TBL] [Abstract][Full Text] [Related]
3. Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders.
Yildirim AM; Koca AO; Beyan E; Dogan O; Karakaya S; Aksoz Z; Ertuğrul DT
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(17):5511-5517. PubMed ID: 34533801
[TBL] [Abstract][Full Text] [Related]
4. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
Girona J; Rodríguez-Borjabad C; Ibarretxe D; Heras M; Amigo N; Feliu A; Masana L; Plana N;
J Clin Lipidol; 2018; 12(1):211-218. PubMed ID: 29102496
[TBL] [Abstract][Full Text] [Related]
5. The Relationship of Circulating Proprotein Convertase Subtilisin/Kexin Type 9 With TSH and Lipid Profile in Newly Diagnosed Patients With Subclinical and Overt Hypothyroidism.
Sadik NA; Rashed LA; El-Sawy SS
Clin Med Insights Endocrinol Diabetes; 2022; 15():11795514221093317. PubMed ID: 35494422
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
Demers A; Samami S; Lauzier B; Des Rosiers C; Ngo Sock ET; Ong H; Mayer G
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2517-25. PubMed ID: 26494228
[TBL] [Abstract][Full Text] [Related]
7. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.
Kwakernaak AJ; Lambert G; Muller Kobold AC; Dullaart RP
Thyroid; 2013 Feb; 23(2):166-72. PubMed ID: 23106476
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.
Ozkan C; Akturk M; Altinova AE; Cerit ET; Gulbahar O; Yalcin MM; Cakir N; Balos Toruner F
Endocr J; 2015; 62(12):1091-9. PubMed ID: 26490048
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
10. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
11. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
[TBL] [Abstract][Full Text] [Related]
12. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
13. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
14. Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome.
Cyr Y; Lamantia V; Bissonnette S; Burnette M; Besse-Patin A; Demers A; Wabitsch M; Chrétien M; Mayer G; Estall JL; Saleh M; Faraj M
Physiol Rep; 2021 Feb; 9(3):e14721. PubMed ID: 33527668
[TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.
de Armas-Rillo L; Quevedo-Abeledo JC; de Vera-González A; González-Delgado A; García-Dopico JA; Jimenez-Sosa A; Rodríguez-Lozano C; González-Gay MA; Ferraz-Amaro I
Rheumatology (Oxford); 2021 May; 60(5):2296-2306. PubMed ID: 33295631
[TBL] [Abstract][Full Text] [Related]
16. Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters.
Bianconi V; Schiaroli E; Pirro M; Cardaci S; Busti C; Mannarino MR; Baldelli F; Francisci D
HIV Med; 2020 Sep; 21(8):512-522. PubMed ID: 32496664
[TBL] [Abstract][Full Text] [Related]
17. [The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis].
Du Q; Yu XJ; Li HJ; Guan SQ; Zhang ZY; Mei YF
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):655-659. PubMed ID: 28870033
[No Abstract] [Full Text] [Related]
18. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
Jin K; Park BS; Kim YW; Vaziri ND
Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
[TBL] [Abstract][Full Text] [Related]
19. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
20. Circulating PCSK9 affects serum LDL and cholesterol levels more than SREBP-2 expression.
Mohammadi A; Shabani M; Naseri F; Hosseni B; Soltanmohammadi E; Piran S; Najafi M
Adv Clin Exp Med; 2017 Jul; 26(4):655-659. PubMed ID: 28691419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
